Mounjaro's active ingredient: what tirzepatide is and how it works

Why two receptors matter: the science behind tirzepatide's dual-agonist design

Most GLP-1 medicines target a single gut-hormone pathway. Tirzepatide was engineered differently. It mimics both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), binding their respective receptors with activity levels that, in combination, appear to produce larger effects on appetite and blood-glucose regulation than GLP-1 alone.

GLP-1 slows gastric emptying and signals fullness to the brain. GIP works in parallel (it influences fat tissue as well as insulin release) and the two pathways appear to reinforce each other. The result, seen in clinical trials, is a degree of appetite suppression and weight reduction that neither pathway achieves individually at the doses studied. You can read more about the pharmacology on the how Mounjaro works page if the mechanism interests you.

Tirzepatide is delivered once weekly as a subcutaneous injection via Mounjaro's pre-filled KwikPen. Each pen contains four weekly doses. Injection sites rotate across the abdomen, thigh and upper arm. Storage is refrigerated at 2–8°C; the exact room-temperature window before a pen must be used is detailed in the Patient Information Leaflet rather than here, because it matters and should be read directly.

The NHS medicines page on tirzepatide covers the patient-level detail on how it works alongside what to expect when you start.

What the trial data on tirzepatide's active ingredient actually showed

SURMOUNT-1 randomised 2,539 adults with obesity (no diabetes) across 2.5, 5, 10 and 15 mg tirzepatide doses versus placebo over 72 weeks. At 15 mg, average body-weight reduction was around 20–21%. That figure comes from a large, controlled setting with lifestyle support alongside the medicine; real-world results vary by individual.

NICE reviewed this evidence in its appraisal of tirzepatide (TA1026, published December 2024) and concluded the clinical data supported recommendation for adults with a BMI of 35 or above plus at least one weight-related condition, with lower BMI thresholds applying for some ethnic backgrounds under UK guidance. That is the NHS eligibility bar; the licensed private-prescription criteria are broader (BMI ≥30, or ≥27 with a qualifying condition).

SURMOUNT-5, a head-to-head trial published in 2025, compared tirzepatide directly with semaglutide 2.4 mg over 72 weeks and found tirzepatide produced greater average weight reduction. These are group averages, how an individual responds depends on dose, adherence, diet, activity and biology. The results and transformation page sets out the evidence in more detail.

For a fuller picture of what is known about tirzepatide as a compound, the tirzepatide overview covers both the weight-management and type 2 diabetes licences.

Excipients and formulation: the other ingredients alongside tirzepatide

Tirzepatide is the active ingredient; everything else in the pen is there to keep it stable and deliverable. The inactive substances (the excipients) include buffering agents, a tonicity agent and water for injections. None of them have a therapeutic effect on weight; their job is formulation chemistry.

If you have a known allergy to any component of the Mounjaro pen, that is something to raise directly with a prescriber before starting. A full excipients list is published in the Mounjaro Summary of Product Characteristics on the eMC. The full ingredients breakdown page goes through the excipients specifically if that is what you need.

The pen itself is a pre-filled, auto-injector device made by Eli Lilly. When it arrives (in plain, unbranded packaging via DPD, tracked to your door) the needle is hidden and the mechanism locks after use. Sharps disposal guidance comes with it. The active ingredient inside, tirzepatide, is the same molecule regardless of which dose strength you are prescribed.

Prescription-only status and what that means in practice

Tirzepatide is a prescription-only medicine under UK law. That classification exists because suitability depends on medical history, current medicines, contraindications and clinical judgement, not just BMI alone. Certain conditions, including a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, and active or recent pancreatitis, require specific discussion with a prescriber before tirzepatide is considered.

Mounjaro also carries the Black Triangle (▼) designation, meaning the MHRA is collecting additional post-marketing safety data. Patients can report any suspected side effects through the Yellow Card scheme. That reporting helps build the real-world evidence base for this relatively new medicine.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a named clinician, not a decision algorithm. If you are considering Mounjaro, the Mounjaro treatment page explains what the consultation involves and what the process looks like from there. If you want to understand the cost context before starting, the Eli Lilly UK price change page covers what happened to market pricing from September 2025 onwards.

To speak to our prescribers about whether tirzepatide is clinically appropriate for you, start your free consultation.